Bob Schneiderman, commented, "We are pleased that our specialty pharmacy continues to report tremendous revenues and is maintaining an annual run rate over $60 million. As ScripsAmerica closes 2014 in a very strong financial position where revenues have experienced dramatic growth, we are currently profitable and have a favorable capital structure with less than 138 million shares outstanding, we believe the company is greatly undervalued right now."

This confirms we are CFP! Go SCRC! Tut